YUKSEL CETİN

Dr. YUKSEL CETİN


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
YCYUKSEL CETİN
YUKSEL CETİN
LBL.B. Bullerman
L.B. Bullerman

6 January 2023 in Polymers
Verified
Journal Article
Open access
PDF file
AZAtefeh Zarepour
Atefeh Zarepour
AEAbdurrahim Can Egil
Abdurrahim Can Egil
MCMelike Cokol Cakmak
Melike Cokol Cakmak
MRMonireh Esmaeili Rad
Monireh Esmaeili Rad
YCYUKSEL CETİN
YUKSEL CETİN
Ali ZarrabiAli Zarrabi
Ali Zarrabi
Changes in weather conditions and lifestyle lead to an annual increase in the amount of lung cancer, and therefore it is one of the three most common types of cancer, making it important to find an appropriate treatment method. This research aims to introduce a new smart nano-drug delivery system with antibacterial and anticancer capabilities that could be applied for the treatment of lung cancer. It is composed of a niosomal carrier containing curcumin as an anticancer drug and is coated with a chitosan polymeric shell, alongside Rose Bengal (RB) as a photosensitizer with an antibacterial feature. The characterization results confirmed the successful fabrication of lipid-polymeric carriers with a size of nearly 80 nm and encapsulation efficiency of about 97% and 98% for curcumin and RB, respectively. It had the Korsmeyer–Peppas release pattern model with pH and temperature responsivity so that nearly 60% and 35% of RB and curcumin were released at 37 °C and pH 5.5. Moreover, it showed nearly 50% toxicity against lung cancer cells over 72 h and antibacterial activity against Escherichia coli. Accordingly, this nanoformulation could be considered a candidate for the treatment of lung cancer; however, in vivo studies are needed for better confirmation.

1 December 2020 in Materialia
Verified
Journal Article
Closed access
YCYUKSEL CETİN
YUKSEL CETİN
AIAhmed Mohamed Hassan Ibrahim
Ahmed Mohamed Hassan Ibrahim
AGAysen Gungor
Aysen Gungor
YYYasemin Yildizhan
Yasemin Yildizhan
MBMartin Balog
Martin Balog
PKPeter Krizik
Peter Krizik

26 May 2021 in Journal of Biomaterials Applications
Verified
Journal Article
Closed access
PDF file
YCYUKSEL CETİN
YUKSEL CETİN
MSMerve G Sahin
Merve G Sahin
FKFatma N Kok
Fatma N Kok
Cardiac tissue engineering focusing on biomaterial scaffolds incorporating cells from different sources has been explored to regenerate or repair damaged area as a lifesaving approach.The aim of this study was to evaluate the cardiomyocyte differentiation potential of human adipose mesenchymal stem cells (hAD-MSCs) as an alternative cell source on silk fibroin (SF) scaffolds for cardiac tissue engineering. The change in surface morphology of SF scaffolds depending on SF concentration (1–6%, w/v) and increase in their porosity upon application of unidirectional freezing were visualized by scanning electron microscopy (SEM). Swelling ratio was found to increase 2.4 fold when SF amount was decreased from 4% to 2%. To avoid excessive swelling, 4% SF scaffold with swelling ratio of 10% (w/w) was chosen for further studies.Biodegradation rate of SF scaffolds depended on enzymatic activity was found to be 75% weight loss of SF scaffolds at the day 14. The phenotype of hAD-MSCs and their multi-linage potential into chondrocytes, osteocytes, and adipocytes were shown by flow cytometry and immunohistochemical staining, respectively.The viability of hAD-MSCs on 3D SF scaffolds was determined as 90%, 118%, and 138% after 1, 7, and 14 days, respectively. The use of 3D SF scaffolds was associated with increased production of cardiomyogenic biomarkers: α-actinin, troponin I, connexin 43, and myosin heavy chain. The fabricated 3D SF scaffolds were proved to sustain hAD-MSCs proliferation and cardiomyogenic differentiation therefore, hAD-MSCs on 3D SF scaffolds may useful tool to regenerate or repair damaged area using cardiac tissue engineering techniques.

28 September 2021 in Phytochemical Analysis
Verified
Journal Article
Open access
PDF file
KDKubra Dogan
Kubra Dogan
EEEBRU EROL
EBRU EROL
MOMuge Didem Orhan
Muge Didem Orhan
ZDZehra Degirmenci
Zehra Degirmenci
TKTugce Kan
Tugce Kan
MGMustafa Guzel
Mustafa Guzel
Introduction: Numerous efforts in natural product drug development are reported for the treatment of Coronavirus. Based on the literature, among these natural plants Artemisia annua L. shows some promise for the treatment of SARS‐CoV‐2.Objective: The main objective of our study was to determine artemisinin content by liquid chromatography electrospray ionisation tandem mass spectrometry (LC‐ESI‐MS/MS), to investigate the in vitro biological activity of artemisinin from the A. annua plants grown in Turkey with various extracted methods, to elaborate in silico activity against SARS‐CoV‐2 using molecular modelling.Methodology: Twenty‐one different extractions were applied. Direct and sequential extractions studies were compared with ultrasonic assisted maceration, Soxhlet, and ultra‐rapid determined artemisinin active molecules by LC‐ESI‐MS/MS methods. The inhibition of spike protein and main protease (3CL) enzyme activity of SARS‐CoV‐2 virus was assessed by time resolved fluorescence energy transfer (TR‐FRET) assay.Results: Artemisinin content in the range 0.062–0.066%. Artemisinin showed significant inhibition of 3CL protease activity but not Spike/ACE‐2 binding. The 50% effective concentration (EC50) of artemisinin against SARS‐CoV‐2 Spike pseudovirus was found greater than 50 μM (EC45) in HEK293T cell line whereas the cell viability was 94% of the control (P < 0.01). The immunosuppressive effects of artemisinin on TNF‐α production on both pseudovirus and lipopolysaccharide (LPS)‐induced THP‐1 cells were found significant in a dose dependent manner.Conclusion: Further studies of these extracts for COVID‐19 treatment will shed light to seek alternative treatment options. Moreover, these natural extracts can be used as an additional treatment option with medicines, as well as prophylactic use can be very beneficial for patients.

8 June 2023 in Materials
Verified
Journal Article
Open access
PDF file
EKEyyup Murat Karakurt
Eyyup Murat Karakurt
YCYUKSEL CETİN
YUKSEL CETİN
AIAlper Incesu
Alper Incesu
HDHuseyin Demirtas
Huseyin Demirtas
MKMehmet Kaya
Mehmet Kaya
Yan HuangYan Huang
Yan Huang
This study investigated the microstructures, mechanical performances, corrosion resistances, and in vitro studies of porous Ti-xNb-10Zr (x: 10 and 20; at. %) alloys. The alloys were fabricated by powder metallurgy with two categories of porosities, i.e., 21–25% and 50–56%, respectively. The space holder technique was employed to generate the high porosities. Microstructural analysis was performed by using various methods including scanning electron microscopy, energy dispersive spectroscopy, electron backscatter diffraction, and x-ray diffraction. Corrosion resistance was assessed via electrochemical polarisation tests, while mechanical behavior was determined by uniaxial compressive tests. In vitro studies, such as cell viability and proliferation, adhesion potential, and genotoxicity, were examined by performing an MTT assay, fibronectin adsorption, and plasmid-DNA interaction assay. Experimental results showed that the alloys had a dual-phase microstructure composed of finely dispersed acicular hcp α-Ti needles in the bcc β-Ti matrix. The ultimate compressive strength ranged from 1019 MPa to 767 MPa for alloys with 21–25% porosities and from 173 MPa to 78 MPa for alloys with 50–56% porosities. Noted that adding a space holder agent played a more critical role in the mechanical behaviors of the alloys compared to adding niobium. The pores were largely open and exhibited irregular shapes, with uniform size distribution, allowing for cell ingrowth. Histological analysis showed that the alloys studied met the biocompatibility criteria required for orthopaedic biomaterial use.